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Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Abstract
BACKGROUND: The expression of interleukin-1-receptor antagonist is reduced in pancreatic islets of
patients with type 2 diabetes mellitus, and high glucose concentrations induce the production of
interleukin-1beta in human pancreatic beta cells, leading to impaired insulin secretion, decreased cell
proliferation, and apoptosis. METHODS: In this double-blind, parallel-group trial involving 70 patients
with type 2 diabetes, we randomly assigned 34 patients to receive 100 mg of anakinra (a recombinant
human interleukin-1-receptor antagonist) subcutaneously once daily for 13 weeks and 36 patients to
receive placebo. At baseline and at 13 weeks, all patients underwent an oral glucose-tolerance test,
followed by an intravenous bolus of 0.3 g of glucose per kilogram of body weight, 0.5 mg of glucagon,
and 5 g of arginine. In addition, 35 patients underwent a hyperinsulinemic-euglycemic clamp study. The
primary end point was a change in the level of glycated hemoglobin, and secondary end points were
changes in beta-cell function, insulin sensitivity, and inflammatory markers. RESULTS: At 13 weeks, in
the anakinra group, the glycated hemoglobin level was 0.46 percentage point lower than in the placebo
group (P=0.03); C-peptide secretion was enhanced (P=0.05), and there were reductions in the ratio of
proinsulin to insulin (P=0.005) and in levels of interleukin-6 (P<0.001) and C-reactive protein
(P=0.002). Insulin resistance, insulin-regulated gene expression in skeletal muscle, serum adipokine
levels, and the body-mass index were similar in the two study groups. Symptomatic hypoglycemia was
not observed, and there were no apparent drug-related serious adverse events. CONCLUSIONS: The
blockade of interleukin-1 with anakinra improved glycemia and beta-cell secretory function and reduced
markers of systemic inflammation. (ClinicalTrials.gov number, NCT00303394 [ClinicalTrials.gov].).
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Background
The expression of interleukin-1–receptor antagonist is reduced in pancreatic islets of 
patients with type 2 diabetes mellitus, and high glucose concentrations induce the 
production of interleukin-1β in human pancreatic beta cells, leading to impaired 
insulin secretion, decreased cell proliferation, and apoptosis.
Methods
In this double-blind, parallel-group trial involving 70 patients with type 2 diabetes, 
we randomly assigned 34 patients to receive 100 mg of anakinra (a recombinant 
human interleukin-1–receptor antagonist) subcutaneously once daily for 13 weeks 
and 36 patients to receive placebo. At baseline and at 13 weeks, all patients under-
went an oral glucose-tolerance test, followed by an intravenous bolus of 0.3 g of 
glucose per kilogram of body weight, 0.5 mg of glucagon, and 5 g of arginine. In 
addition, 35 patients underwent a hyperinsulinemic–euglycemic clamp study. The 
primary end point was a change in the level of glycated hemoglobin, and secondary 
end points were changes in beta-cell function, insulin sensitivity, and inflammatory 
markers.
Results
At 13 weeks, in the anakinra group, the glycated hemoglobin level was 0.46 per-
centage point lower than in the placebo group (P = 0.03); C-peptide secretion was 
enhanced (P = 0.05), and there were reductions in the ratio of proinsulin to insulin 
(P = 0.005) and in levels of interleukin-6 (P<0.001) and C-reactive protein (P = 0.002). 
Insulin resistance, insulin-regulated gene expression in skeletal muscle, serum 
adipokine levels, and the body-mass index were similar in the two study groups. 
Symptomatic hypoglycemia was not observed, and there were no apparent drug-
related serious adverse events.
Conclusions
The blockade of interleukin-1 with anakinra improved glycemia and beta-cell secre-
tory function and reduced markers of systemic inflammation. (ClinicalTrials.gov 
number, NCT00303394.)
Copyright © 2007 Massachusetts Medical Society. All rights reserved. 
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T ype 2 diabetes mellitus occurs when beta-cell function fails to compensate for insulin resistance.1,2 Beta-cell function pro-
gressively deteriorates with an increasing dura-
tion of diabetes,3 partly because of beta-cell demise 
through apoptosis.4-6
Interleukin-1β, a proinflammatory cytokine7 
implicated as an effector molecule of inflam-
matory beta-cell destruction leading to type 1 dia-
betes,8 inhibits the function and promotes the 
apoptosis of beta cells.9 Beta cells producing inter-
leukin-1β have been observed in pancreatic sec-
tions obtained from patients with type 2 diabe-
tes.10 Depending on culture conditions, high 
glucose levels increase beta-cell production and 
the release of interleukin-1β, followed by func-
tional impairment and apoptosis.10-13 These find-
ings suggest that intra-islet production of inflam-
matory mediators has a role in the pathogenesis 
of type 2 diabetes and that interleukin-1β is a 
potential therapeutic target for preserving beta-
cell mass and function in patients with this con-
dition.
Interleukin-1–receptor antagonist, a naturally 
occurring competitive inhibitor of interleukin-1 
binding to the type I receptor,7,14 protects human 
beta cells from glucose-induced functional im-
pairment and apoptosis.10 Interleukin-1–receptor 
antagonist is reported to have no agonistic activ-
ity.7,15 The expression of interleukin-1–receptor 
antagonist is decreased in beta cells obtained 
from patients with type 2 diabetes.16 Given these 
observations, we hypothesized that intervening in 
the islet balance between interleukin-1–receptor 
antagonist and interleukin-1β might improve beta-
cell function and glycemic control in patients with 
type 2 diabetes.
Me thods
Study Design
This placebo-controlled, double-blind, parallel-
group study involved 70 patients with type 2 dia-
betes at two centers (31 patients in Denmark and 
39 patients in Switzerland) who were recruited 
from January 2004 to March 2005. Patients re-
ceived either once-daily recombinant human inter-
leukin-1–receptor antagonist (100 mg of anakinra 
[Kineret] donated by Amgen) or placebo by sub-
cutaneous self-administration in the morning for 
13 weeks. Patients continued their baseline anti-
diabetic therapy, dietary habits, and other lifestyle 
habits.
The County Pharmacy of Zurich was responsi-
ble for the blinding and randomization procedure; 
the latter was performed with the use of permut-
ed blocks within the recruiting center. The au-
thors designed the study, gathered and analyzed 
the data, wrote the manuscript, and vouch for the 
accuracy and completeness of the data and the 
analysis. There was no confidentiality agreement 
between the authors or their institutions and 
Amgen, which provided the study drugs.
Patients
We conducted the study in accordance with the 
ethical guidelines of the Declaration of Helsinki 
II; the study design was approved by regional and 
institutional review boards. Written informed con-
sent was obtained from all patients before ran-
domization.
The inclusion criteria were an age of 20 years 
or more, type 2 diabetes diagnosed according to 
American Diabetes Association criteria17 with a 
duration of more than 3 months, a body-mass 
index (BMI, the weight in kilograms divided by 
the square of the height in meters) of more than 
27, and a glycated hemoglobin level of more than 
7.5% (upper limit of the normal range, 6.4%). 
Eligible patients had had no changes in either 
types or doses of medications during the 3-month 
period preceding the study.
The exclusion criteria were the presence of 
autoantibodies to glutamic acid decarboxylase 65 
or islet-cell autoantibody-2; a glycated hemoglobin 
level of more than 12%; a fasting C-peptide level 
of less than 400 pmol per liter; current treatment 
with antiinflammatory drugs, including cortico-
steroids and nonsteroidal antiinflammatory drugs 
(100 mg or less of aspirin per day was allowed); 
signs of current infection, including a C-reactive 
protein level of more than 30 mg per liter, fever, 
current treatment with antibiotics, chronic gran-
ulomatous infections (e.g., a previous diagnosis 
of tuberculosis or a current diagnosis based on 
chest radiography or a Mantoux test); a history of 
recurrent infection or a predisposition to infec-
tion; neutropenia (a leukocyte count of less than 
2000 per cubic millimeter) or anemia (a hemo-
globin level of less than 11 g per deciliter for men 
and less than 10 g per deciliter for women); 
pregnancy or breast-feeding (contraception for 
at least 3 months before inclusion was required 
for fertile women); liver or renal disease (a level 
of aspartate aminotransferase or alanine amino-
transferase of more than three times the upper 
Copyright © 2007 Massachusetts Medical Society. All rights reserved. 
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limit of the normal range and a serum creati-
nine level of more than 130 μmol per liter); on-
going or previous cancer; the use of any other 
investigational drug within 30 days before en-
rollment or within five half-lives of the medica-
tion used in the other study, whichever was the 
longer period; and immunosuppressive treatment 
or immunodeficiency.
Study Procedures
At baseline and 13 weeks, a 2-hour oral glucose-
tolerance test was performed with 75 g of glucose, 
followed by measurements of plasma glucose, pro-
insulin, insulin, and C-peptide 10 minutes before 
and during the test and measurements of plasma 
glucose, insulin, and C-peptide 30, 60, 90, and 
120 minutes after the test. Immediately after the 
end of the oral glucose-tolerance test, an intrave-
nous injection of 0.3 g of glucose per kilogram of 
body weight, 0.5 mg of glucagon, and 5 g of argi-
nine was administered. Blood was then sampled 
at 0, 3, 6, 9, and 12 minutes. The patients were 
asked to forgo their antidiabetic medication and 
to fast for 8 to 9 hours before the test.
At baseline and 13 weeks, euglycemic–hyper-
insulinemic clamp studies18 and muscle biopsies 
were performed. All patients were asked to par-
ticipate in the clamp and muscle-biopsy studies, 
although participation in these studies was not 
a requirement for remaining in the overall study. 
The patients were required to forgo antidiabetic 
treatment for 8 to 9 hours and to avoid strenuous 
physical exercise for 24 hours before the clamp 
study. The clamp procedure was performed 2 to 
7 days after the oral glucose-tolerance test. Indi-
rect calorimetry was performed during the insu-
lin-stimulated 30-minute steady-state period. The 
insulin-sensitivity index during the clamp proce-
dure was calculated by dividing the M value (the 
glucose infusion rate during the steady-state 
period divided by the total body weight) by the 
steady-state plasma insulin level.
Biopsy specimens were obtained from the vas-
tus lateralis muscle immediately after the ad-
ministration of the intravenous bolus at the end 
of the oral glucose-tolerance test. Messenger RNA 
(mRNA) from glucose transporter 4 (GLUT4) and 
peroxisome-proliferator–activated receptor γ co-
activator 1α (PGC-1α)19,20 was quantified as de-
scribed in the Supplementary Appendix (avail-
able with the full text of this article at www.
nejm.org).
Levels of C peptide, insulin, and proinsulin 
were determined centrally at the Steno Diabetes 
Center. Insulin and proinsulin were assessed by 
enzyme-linked immunosorbent assays,21,22 and 
C-peptide levels were determined by a time-resolved 
fluoroimmunoassay.23 Measurements of glycated 
hemoglobin levels and routine clinical laboratory 
tests were performed in the central laboratory 
units of the two participating centers. For glycat-
ed hemoglobin, 22 coded samples from patients 
were tested at both laboratories. Regression analy-
sis showed an r2 value of 0.97 for agreement be-
tween the test results (P<0.001). Serum adipo-
kines were assayed with the use of Luminex 
technology (Millipore) according to the manufac-
turer’s instructions.
A physical examination and blood tests were 
performed at baseline and at 4 and 13 weeks. 
Fasting plasma glucose levels were measured 
weekly at home by the patients. At baseline and 
13 weeks, funduscopy was performed, and uri-
nary albumin excretion, creatinine clearance, and 
(in women) human chorionic gonadotropin were 
measured.
Study End Points
The predefined primary end point was the change 
in the glycated hemoglobin level between baseline 
and 13 weeks. Predefined secondary end points 
included a change by week 13 in the area under 
the concentration–time curve (AUC) for stimulat-
ed C-peptide during an oral glucose-tolerance test 
and after intravenous stimulation, a change in the 
ratio of fasting proinsulin to insulin, a change in 
the insulin-sensitivity index derived from the oral 
glucose-tolerance test,24 a change in serum adipo-
kine levels, a change in insulin sensitivity as as-
sessed by a euglycemic–hyperinsulinemic clamp 
study (in the 35 patients who provided consent 
for this procedure), a change in insulin-regulated 
genes in biopsy specimens obtained from skele-
tal muscle, and changes in levels of fasting plasma 
glucose, interleukin-6, and C-reactive protein as 
markers of systemic inflammation.
Statistical Analysis
No interim analyses were carried out in this study. 
Data from all patients were analyzed. Values are 
expressed as means (±SD) unless otherwise spec-
ified. Differences were tested with the use of an 
unpaired t-test and with a Wilcoxon rank-sum test 
in the case of non-normal distribution. For cate-
gorical end points, Pearson’s chi-square test was 
used. Correlations were performed by regression 
Copyright © 2007 Massachusetts Medical Society. All rights reserved. 
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analysis. To analyze the effect of baseline charac-
teristics on the primary end point, bivariate re-
gression analyses including the treatment effect 
were performed. A P value of less than 0.05 was 
considered to indicate statistical significance. All 
reported P values are two-sided and have not been 
adjusted for multiple testing.
R esult s
Baseline Characteristics and Adherence
Seventy of the 124 subjects who underwent initial 
screening were randomly assigned to receive ei-
ther anakinra or placebo (Fig. 1). In the placebo 
group, a late positive Mantoux reaction developed 
in one patient, suggesting a reactivation of tuber-
culosis, and the patient was excluded before start-
ing study medication. Table 1 shows the baseline 
characteristics of the two study groups after ran-
domization.
All 34 patients receiving anakinra completed 
the study, as did 33 of 35 patients receiving pla-
cebo. In the placebo group, a phlegmonous foot 
infection developed in one patient after 4 weeks, 
and one patient identified his study-group assign-
ment by performing a biochemical analysis of the 
study drug after 5 weeks. Two patients in the 
anakinra group and one in the placebo group re-
duced the dose of their antidiabetic medication 
during the intervention because of improvement 
in glycemia but were not excluded from the study, 
according to the intention-to-treat principle. The 
remaining patients did not change their antidia-
betic therapy during the 13-week study period, as 
reflected by recorded types and doses of antidia-
betic medication at baseline and at 4 and 13 weeks 
(data not shown). Thirty-five subjects (16 in the 
anakinra group and 19 in the placebo group) gave 
informed consent to participate in the clamp and 
muscle-biopsy studies. The patients who provided 
consent did not differ in their baseline character-
istics from those who declined (data not shown). 
The peak serum levels of interleukin-1–receptor 
antagonist, measured 1 to 2 hours after the last 
injection of anakinra or placebo at 13 weeks, were 
1256±958 μg per liter in the anakinra group and 
0.6±0.4 μg per liter in the placebo group (P< 
0.001).
Primary End Point
The average absolute difference in glycated hemo-
globin levels between baseline and 13 weeks was a 
reduction of 0.33 percentage point (from 8.69±0.17 
to 8.37±0.21) in the anakinra group and an in-
crease of 0.13 percentage point (from 8.23±0.28 
to 8.37±0.46) in the placebo group, yielding a be-
tween-group difference of 0.46 percentage point 
(95% confidence interval [CI], 0.01 to 0.90; 
P = 0.03) (Fig. 2A). The number of patients who 
had any reduction in glycated hemoglobin levels 
22p3
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Figure 1. Enrollment and Outcomes.
A total of 312 patients with type 2 diabetes mellitus were recruited either in 
the outpatient clinics of the two participating centers or through newspaper 
advertisements. Of those, 188 patients did not respond, were not interest-
ed, or were not eligible on the basis of their medical history. Of the 124 pa-
tients who underwent physical and biochemical screening, 54 were found 
to be ineligible according to entry criteria, in most cases becau e they had 
either a glycated hemoglobin level of less than 7.5% or a fasting C-peptide 
level of less than 400 pmol per liter. Seventy patients were randomly assigned 
to receive either anakinra or placebo. In the placebo group, one patient was 
excluded before starting study medication and two patients withdrew after 
4 and 5 weeks of treatment. A total of 67 patients completed the 13-week 
treatment and evaluation of study end points.
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at 13 weeks was 21 of 34 patients in the anakinra 
group, as compared with 10 of 33 patients in the 
placebo group (P<0.001). Glycated hemoglobin 
levels were significantly lower in the anakinra 
group after 4 weeks than in the placebo group 
(an absolute reduction of 0.36%; 95% CI, 0.11 to 
0.60; P = 0.004) (Fig. 2A). When the patients were 
stratified into three equal groups according to 
body-surface area as a surrogate for drug distri-
bution volume, the difference in glycated hemo-
globin levels in the anakinra group was a reduc-
tion of 0.84% in the lowest third (<2.00 m2), a 
reduction of 0.30% in the intermediate group 
(2.00 to 2.24 m2), and an increase of 0.11% in the 
highest third (>2.24 m2) (P = 0.02 for all compari-
sons) (Fig. 2C). Accordingly, body-surface area cor-
related with the changes in glycated hemoglobin 
levels in the anakinra group (r2 = 0.22, P = 0.007) 
but not in the placebo group (r2 = 0.001, P = 0.87).
Secondary End Points
Glycemia
Fasting plasma glucose levels that were measured 
by the patients at home once weekly were consis-
tently lower in the anakinra group than in the 
placebo group (Fig. 2B). At 13 weeks, plasma glu-
Table 1. Baseline Characteristics of the Patients.*
Characteristic Anakinra (N = 34) Placebo (N = 35) P Value
Age (yr) 60.6±8.7 60.3±8.6 0.89
Sex (no.)
Male 23 27
Female 11  8 0.39
Body-mass index 31.5±5.2 31.8±4.4 0.82
Weight (kg)  94.5±16.7 97.0±9.0 0.43
Glycated hemoglobin (%)  8.7±1.0  8.2±0.9 0.05
Fasting plasma glucose (mmol/liter) 10.8±2.7 10.0±3.1 0.24
Fasting C-peptide (pmol/liter)  958±312  907±508 0.62
Diabetes duration (yr) 10.6±6.2 11.0±7.3 0.82
Smoking status (%)
Current 15 17
Former 41 33 0.79
Cholesterol (mmol/liter)
Total  4.65±1.12  4.86±1.42 0.50
HDL  1.35±1.27  1.09±0.33 0.25
Creatinine (μmol/liter)  91.5±21.5  94.3±21.9 0.60
Blood pressure (mm Hg)
Systolic 145.8±15.9 146.4±18.7 0.89
Diastolic 83.4±7.9 82.7±8.2 0.75
Use of antihypertensive medication (%) 71 74 0.73
History of cardiovascular disease (%) 47 23 0.04
Albumin excretion rate >30 mg/liter/24 hr (%) 33 32 0.93
Retinopathy (%) 21 31 0.31
Antidiabetic treatment (%) 0.53
Diet  9  6
Oral drug 53 43
Insulin (alone or with oral drug) 38 51
* Plus–minus values are means ±SD. The body-mass index is the weight in kilograms divided by the square of the height 
in meters. To convert cholesterol values to milligrams per deciliter, divide by 0.02586. To convert creatinine values to 
milligrams per deciliter, divide by 88.4. HDL denotes high-density lipoprotein.
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cose levels at the beginning and end of a 2-hour 
oral glucose-tolerance test were reduced by 0.6 mM 
(95% CI, 0.05 to 1.60; P = 0.29) and 1.3 mM (95% 
CI, 0.00 to 2.6; P = 0.05), respectively, in the ana-
kinra group, as compared with the placebo group.
Beta-Cell Secretory Function
At 13 weeks, beta-cell function increased in the 
anakinra group and decreased in the placebo group 
(Fig. 3). In particular, the ratio of proinsulin to in-
sulin was markedly lower in the anakinra group 
(P = 0.005). The changes in beta-cell function as-
sessed on the basis of the AUC from the oral 
glucose-tolerance test and intravenous tests were 
significantly correlated (P<0.001) (data not shown). 
The change in beta-cell function was correlated 
with changes in glycated hemoglobin levels in pa-
tients in the anakinra group but not in the placebo 
group. The correlation between the change in gly-
cated hemoglobin levels and the AUC for stimu-
lated C-peptide during the oral glucose-tolerance 
test was r2 = 0.13 (P = 0.04) in the anakinra group 
and r2 = 0.04 (P = 0.76) in the placebo group; the cor-
relation for intravenous stimulation was r2 = 0.32 
(P<0.001) in the anakinra group and r2 = 0.03 
(P = 0.29) in the placebo group; and the correlation 
for the two tests combined was r2 = 0.18 (P = 0.02) 
in the anakinra group and r2 = 0.01 (P = 0.59) in 
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Figure 2. Changes in Glycated Hemoglobin and Fasting Plasma Glucose Levels during the 13-Week Study Period.
Panel A shows the average absolute difference in glycated hemoglobin levels between baseline and 4 and 13 weeks 
in each study group. Panel B shows the average absolute differences in fasting plasma glucose levels between the 
baseline value and weekly measurements performed by the patients at home during the 13-week study period. Pan-
els C and D show the average absolute differences in glycated hemoglobin levels at 13 weeks in each study group 
stratified into thirds according to body-surface area. In the placebo group, the analysis included 35 patients at week 
4, 34 at week 5, and 33 at week 13. In the anakinra group, the analysis included 34 patients at each weekly measure. 
The I bars indicate standard errors.
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the placebo group. Baseline glycated hemoglobin 
values did not correlate with the beta-cell secre-
tion tests in patients in the anakinra group. The 
correlation between the starting glycated hemo-
globin level and the AUC for stimulated C-pep-
tide during the oral glucose-tolerance test was 
r2 = 0.05 (P = 0.22), the correlation for intravenous 
stimulation was r2 = 0.09 (P = 0.10), and the cor-
relation for both tests combined was r2 = 0.06 
(P = 0.17).
Insulin Sensitivity
With the dose of anakinra used in this study, no 
differences in insulin sensitivity were found at 13 
weeks. The M value divided by the plasma insulin 
level during the steady-state period in the euglyce-
mic–hyperinsulinemic clamp study was reduced 
by 0.13±1.76 μg of glucose per kilogram of body 
weight per picomole of insulin per minute in the 
anakinra group and by 0.56±2.52 μg of glucose 
per kilogram of body weight per picomole of insu-
lin per minute in the placebo group (P = 0.58). The 
insulin-sensitivity index, as calculated by the ho-
meostasis model assessment (HOMA) on the basis 
of the oral glucose-tolerance test in all patients, 
increased by 0.003±0.179 square liter per milliunit 
of insulin per millimole of glucose in the anakinra 
group and by 0.029±0.228 square liter per milliunit 
of insulin per millimole of glucose in the placebo 
group (P = 0.60). The insulin-sensitivity index on 
the basis of data from the oral glucose-tolerance 
test strongly correlated with the clamp data 
(r2 = 0.53, P<0.001). There was no correlation be-
tween insulin sensitivity as determined by the 
clamp method and the primary end point at 13 
weeks (r2 = 0.005, P = 0.60) and no change in oxida-
tion rates of glucose, with an increase of 0.02±0.7 
mg of oxidized glucose per kilogram per minute 
in the anakinra group and a decrease of 0.15±0.37 
mg per kilogram per minute in the placebo group 
(P = 0.44) or of fat, with a decrease of 0.05±0.26 
mg per kilogram per minute in the anakinra group 
and an increase of 0.03±0.2 mg per kilogram per 
minute in the placebo group (P = 0.36).
Markers of Systemic Inflammation
Levels of C-reactive protein were significantly 
lower after 4 and 13 weeks in the anakinra group 
than in the placebo group (P = 0.02 after 4 weeks 
and P = 0.002 after 13 weeks) (Fig. 4A). Similar 
declines in interleukin-6 levels were observed 
(P<0.001 after both 4 and 13 weeks) (Fig. 4B). 
Neither baseline values nor changes in levels of 
C-reactive protein or interleukin-6 were signifi-
cantly correlated with changes in glycated hemo-
globin in the anakinra group: r2<0.001 (P = 0.89) for 
baseline C-reactive protein levels, r2<0.001 (P = 0.95) 
for changes in C-reactive protein, r2 = 0.005 (P = 0.70) 
for baseline interleukin-6, and r2 = 0.001 (P = 0.86) 
for changes in interleukin-6. As previously ob-
served,25 neutrophil and platelet counts were slight-
ly and reversibly decreased during anakinra ther-
apy. Neutrophil counts decreased by 1200±1400 
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Figure 3. Beta-Cell Secretory Function.
Beta-cell secretory function was assessed by analysis of the ratio of pro-
insulin to insulin and by a 2-hour oral glucose-tolerance test, followed by 
intravenous stimulation with 0.3 g of glucose per kilogram of body weight, 
0.5 mg of glucagon, and 5 g of arginine. Average absolute differences be-
tween baseline and 13 weeks in each study group are shown, including the 
change in the ratio of proinsulin to insulin (Panel A), the change in the 
area under the concentration–time curve (AUC) for C-peptide i  response 
to a 2-hour oral glucose-tolerance test (Panel B), the change in the AUC 
for C-peptide in response to an intravenous (IV) stimulation test (Panel C), 
and the change in the AUC for the combination of oral and intravenous 
stimulation (Panel D). The analysis included 33 patients in the placebo group 
and 34 in the anakinra group. he I bars indicate standard errors.
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per cubic millimeter in the anakinra group and 
by 100±1300 per cubic millimeter in the placebo 
group; platelet counts decreased by 16,000±25,400 
per cubic millimeter in the anakinra group and 
increased by 3000±23,000 per cubic millimeter in 
the placebo group (P<0.001).
Insulin-Regulated Gene Expression
Treatment with anakinra for 13 weeks did not 
significantly change the mRNA expression levels 
of the insulin-regulated genes GLUT4 (P = 0.81) and 
PGC-1α (P = 0.26) in biopsy specimens of skeletal 
muscle, with decreases of 0.23±1.43 for the rela-
tive expression levels of GLUT4 and 0.12±0.87 for 
PGC-1α normalized to the housekeeping gene 
cyclophilin A in the anakinra group, as compared 
with decreases of 0.34±0.72 in the expression lev-
els of GLUT4 and 0.52±0.79 for PGC-1α in the 
placebo group.
Serum Adipokines
Levels of serum adipokines were not significantly 
changed at 13 weeks in either the anakinra group 
or the placebo group. The levels changed as fol-
lows for the comparison between the study groups: 
leptin, a decrease of 0.40±6.86 ng per milliliter in 
the anakinra group and an increase of 2.81±10.98 
ng per milliliter in the placebo group (P = 0.16); 
adiponectin, an increase of 3.69±11.36 μg per 
milliliter in the anakinra group and a decrease of 
1.00±8.59 μg per milliliter in the placebo group 
(P = 0.07); resistin, a decrease of 2.80±8.56 ng per 
milliliter in the anakinra group and an increase 
of 0.27±7.65 ng per milliliter in the placebo group 
(P = 0.14); tumor necrosis factor α, a decrease of 
0.13±1.44 pg per milliliter in the anakinra group 
and an increase of 0.11±1.56 pg per milliliter in 
the placebo group (P = 0.52); monocyte chemotac-
tic factor 1, an increase of 9.2±50.8 pg per milli-
liter in the anakinra group and a decrease of 
3.3±93.0 pg per milliliter in the placebo group 
(P = 0.50); and interleukin-8, a decrease of 0.81±4.55 
pg per milliliter in the anakinra group and a de-
crease of 0.08±1.17 pg per milliliter in the placebo 
group (P = 0.40).
Other Outcomes
The baseline body weight and BMI were signif-
icantly correlated with changes in glycated he-
moglobin levels (covariate effect, P = 0.003 and 
P = 0.004, respectively; treatment effect, P = 0.08 
and P = 0.05, respectively; and combined effect, 
P = 0.001 and P = 0.002, respectively). This corre-
lation was not observed for the other baseline 
variables.
Adverse Events
There were no significant changes in BMI in either 
group from baseline to 13 weeks, with levels chang-
ing from 31.5±5.2 to 31.8±5.6 in the anakinra 
group (P = 0.82) and 31.8±4.4 to 32.0±4.4 in the 
placebo group (P = 0.85) (P = 0.38 for the compari-
son between study groups). No patient withdrew 
from the study because of drug-related adverse 
events. In particular, symptomatic hypoglycemia 
was not observed, even in patients with a marked 
improvement in glycated hemoglobin levels. All 
reported adverse events are listed in Table 2. In the 
anakinra group, the improvement in glycated 
hemoglobin levels did not differ between patients 
who had injection-site reactions and those who 
did not. There was a decrease of 0.24±0.18% in the 
glycated hemoglobin level in patients with injec-
tion-site reactions and a decrease of 0.64±0.32% 
in those without injection-site reactions (P = 0.54). 
No changes were observed in blood pressure or 
heart rate or in levels of serum sodium, potassium, 
aspartate aminotransferase, alanine aminotrans-
ferase, lipids (including free fatty acids, total cho-
lesterol, high-density lipoprotein, low-density lipo-
protein, and triglycerides), cystatin C, or creatinine 
or in creatinine clearance, 24-hour urinary albu-
min excretion, or retinal fundus. Total hemoglo-
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Figure 4. Markers of Systemic Inflammation.
The average absolute differences between baseline and 4 and 13 weeks in each 
study group are shown for levels of circulating C-reactive protein (Panel A) 
and interleukin-6 (Panel B). In the placebo group, the analysis included 35 
patients at week 4 and 33 at week 13. In the anakinra group, the analysis in-
cluded 34 patients at weeks 4 and 13. The I bars indicate standard errors.
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bin was unchanged, a finding that made changes 
in erythrocyte turnover unlikely as a confounder.
Discussion
Our study shows that antagonism of interleukin-1 
signaling with anakinra improved glycemic con-
trol in patients with type 2 diabetes, most likely 
through enhanced beta-cell secretory function. In-
deed, improved glycemia in patients who received 
anakinra correlated with improved measures of 
beta-cell secretory capacity. There were no altera-
tions in insulin sensitivity on the basis of insulin 
clamp studies, insulin sensitivity indexes modeled 
on the oral glucose-tolerance test, insulin-regu-
lated gene expression in skeletal muscle, or serum 
adipokine levels. Finally, the BMIs of patients re-
mained stable, thus excluding an anorexigenic 
effect of anakinra. However, we cannot exclude 
the possibility that higher doses of anakinra might 
improve insulin sensitivity.
Neither baseline levels of C-reactive protein or 
interleukin-6 nor changes in the levels correlated 
with changes in glycated hemoglobin levels, sug-
gesting that reduced systemic inflammation did 
not play an important part in improved insulin 
secretion. Genetic ablation of systemic interleu-
kin-1 action causes obesity.26,27 It has therefore 
been proposed that interleukin-1 regulates body 
composition and fat distribution, mainly through 
the regulation of feeding behavior, satiety regula-
tion, and energy metabolism, including thermo-
genesis. The integral physiological measure of 
these actions is body weight. In our study, the in-
hibition of the action of interleukin-1 by anakinra 
did not increase body weight.
Limitations of our study include its short dura-
tion and the lack of dose finding. Considering the 
short half-life of anakinra (6 to 8 hours), it is pos-
sible that higher doses or longer-lasting antago-
nism of interleukin-1 might improve the outcome.28 
The association between body weight or body-
surface area at baseline and the glycemic outcome 
suggests that the anakinra dose might be increased 
according to the drug-distribution volume.
Apart from self-limited local reactions at the 
injection site, we observed no clear difference in 
the frequency of adverse events between the ana-
kinra group and the placebo group. No patient 
stopped treatment because of adverse reactions. 
Symptomatic hypoglycemia was not reported by 
any patient. A potential concern with the use of 
interleukin-1 blockade is the inhibition of innate 
immunity and the occurrence of infection. How-
ever, in more than 100,000 patients with rheuma-
toid arthritis who underwent long-term treatment 
with anakinra, there was no significant increase 
in the incidence of infectious disease, despite con-
comitant immunosuppression.28
In summary, our study suggests that antago-
nism of interleukin-1 has possible therapeutic 
potential in the treatment of type 2 diabetes. Fur-
ther studies are needed to test higher doses of 
anakinra, to evaluate its long-term use, and to 
test interleukin-1 antagonists that have a pro-
longed half-life, with the aim of preventing beta-
cell destruction and promoting beta-cell regener-
ation in type 2 diabetes.
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Table 2. Adverse Events.
Event Anakinra  (N = 34)
Placebo  
(N = 35)
no. of patients
Transient injection-site reactions* 17 0
Minor injection-site hematoma  1 0
Mild nausea  1 0
Transient peripheral facial-nerve palsy (day 40)  1 0
Urinary tract infection (days 26–28)  1 0
Upper respiratory tract infection (days 41–45)  1 0
Transient mild elevation of aspartate amino-
transferase (day 87)  1 0
Dry cough  0 1
Peroneal-nerve palsy  0 1
Calf pain  0 1
Phlegmonous foot infection  0 1
* The reactions were first seen between days 6 and 14 and disappeared between 
days 19 and 38.
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